Catherine Bhatt

Catherine Bhatt investigates the role of beta-adrenergic signaling in cancer progression and how propranolol and other beta-blockers may slow cancer progression by blocking stress-induced catecholamine signaling. Her research has characterized how beta-adrenergic receptor activation in cancer cells and stromal cells promotes invasion, angiogenesis, and immune suppression. She leads clinical trials of propranolol in combination with immunotherapy for melanoma and breast cancer. Her work bridges the fields of psycho-oncology, neuro-immunology, and cancer biology.